

IP_OCS/SHD/001/2026

April 2, 2026

Subject: Invitation to 2026 Annual General Meeting of Shareholders

Dear Shareholders of Inter Pharma Public Company Limited

Attachment:

1. A copy of the Minute of the 2025 Annual General Meeting of Shareholders
2. QR Code Downloading Procedures for Annual Report 2025 (Form 56-1 One Report)
3. Profiles and working experiences of the candidates nominated for election as the directors in place of those who retire by rotation
4. Profiles of the Auditors proposed for the year 2026
5. Summary of details of the warrants to purchase the Company's ordinary shares, which are allocated to executives and/or employees of the Company or its subsidiaries (IP ESOP-W1)
6. Capital Increase Report Form (F 53-4)
7. Profiles of the Independent Directors who has been proposed to be proxies of shareholders
8. Proxy Forms (Form A, Form B, and Form C)
9. Article of Association of the Company only to the extent relating to the Shareholders Meeting
10. Procedures for attending the meeting via electronic means (E-Meeting) and proxy appointment
11. Requisition Form for 56-1 One Report 2025
12. Personal Data Protection Notice for the Shareholder Meeting
13. Quidlab E-Meeting & Voting System User's Manual Conferencing Option

The Board of Directors' Meeting of Inter Pharma Public Company Limited ("the Company") No. 1/2026 on March 2, 2026 passed a resolution to call for the 2026 Annual General Meeting of Shareholders through E-Meeting as a sole meeting format in accordance with the criteria stipulated by the relevant laws on Monday, April 27, 2026, at 14.00 hrs., broadcast live at the conference room No. 140/9 ITF Tower, 9 Floor, Silom Road, Suriyawongse, Bangrak, Bangkok 10500, with the agenda as follows:

Agenda 1: To consider and adopt the Minutes of the 2025 Annual General Meeting of Shareholders

Objective and Rationale: The Company prepares the minutes of the 2025 Annual General Meeting of Shareholders on April 28, 2025, submitted to the Stock Exchange of Thailand on May 9, 2025, and publicly disclosed on the Company's website www.interpharma.co.th, details as per **Attachment No. 1**.

Opinion of the Board of Directors: The Board of Directors has considered and is of the opinion that the Minutes of the 2025 Annual General Meeting of Shareholders, held on April 28, 2025, were accurately recorded. It is therefore deemed appropriate to propose that the Annual General Meeting of Shareholders consider and approve the said Minutes.

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 2: To acknowledge the reports of board of directors and operating results for the year ended 31 December 2025

Objective and Rationale: The Company has prepared a report on its annual operating results ending on December 31, 2025, which shows the Company's operating results for the year 2025 as shown in the Form 56-1 One Report 2025.

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to acknowledge the Company's operating results for the year 2025. Details are as shown in the Annual Registration Statement /Annual Report 2025 (Form 56-1 One Report 2025) (downloaded from the QR Code in **Attachment No. 2**)

Voting: This agenda is for acknowledgement and therefore there is no voting.

Agenda 3: To consider and approve the financial statements for the year ended 31 December 2025

Objective and Rationale: According to Section 112 of the Public Limited Company Act B.E. 2535 (1992) (including any amendment thereto) and Article 46 of the Company's Articles of Association, the Company has to prepare the Financial Statements as of the date ending the Company's accounting period for submission to the shareholders' meeting for consideration and approval.

Opinion of the Audit Committee: The Audit Committee Meeting No. 1/2026 held on March 2, 2026 has reviewed the Company and the subsidiaries' financial statements for the year ended December 31, 2025 as proposed by the Company's auditor and found that they were accurate and credible, as well as disclosed adequate information.

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the Financial Statements for the year ended December 31, 2025, as duly audited and certified by the auditor from EY Office Limited and reviewed by the Audit Committee. Details are as shown in the Annual Registration Statement /Annual Report 2025 (Form 56-1 One Report 2025) (downloaded from the QR Code in **Attachment No. 2**)

The summary of the Company's financial status and performance as follows:

		Consolidated Financial Statement		Separate Financial Statement	
		2025	2024	2025	2024
Total Assets	(Million Baht)	3,238.81	3,026.84	2,311.86	2,225.68
Total Liabilities	(Million Baht)	939.83	869.06	310.74	298.09
Total Revenue	(Million Baht)	2,214.06	1,911.95	734.75	653.47
Profit (Loss) for the year	(Million Baht)	136.07	36.63	73.65	25.31
Earning (Loss) per share	(Baht : Share)	0.202	0.061	0.122	0.042

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 4: To consider and approve the allocation of profit as legal reserve and dividend payment for the year 2025

Objective and Rationale: According to Section 115 of the Public Limited Company Act B.E. 2535 (1992) (as amended) and Article 51 of the Company's Articles of Association, provide that no dividends shall be paid other than out of profits. The Company's policy is to pay dividends at the rate of not less than 50 percent of the net profits after deducting the legal reserves and, provided that dividend payment will be subjected to the Company's cash flow, investment plan, conditions and terms of agreements to which the Company is bound, as well as the necessity and other appropriateness in the future.

And according to Section 116 of the Public Limited Company Act B.E. 2535 (1992) (including any amendment thereto) and Article 53 of the Company's Articles of Association, the Company must allocate part of the annual net profit as reserve fund in an amount not less than 5 percent of the annual net profit less the sum of accumulated loss brought forward (if any) until the reserve fund amounts to be not less than 10 percent of the registered capital.

Opinion of the Board of Directors: The Board of Directors has considered and deemed it appropriate to propose to the Annual General Meeting of Shareholders for approval the payment of dividends for the operating results of 2025 at the rate of Baht 0.073 per share for a total of 605,344,475 shares, amounting to approximately Baht 44.19 million in total, or equivalent to 60% of the net profit after the deduction of all types of reserves as required by the Company's Articles of Association and applicable laws. This is in accordance with the Company's dividend payment policy. The Board also approved the allocation of Baht 3.68 million from the net profit for 2025 as a statutory reserve.

The Board of Directors has set the Record Date on May 7, 2026 to determine the name of shareholders who are entitled to receive the dividend and to pay the dividend on May 25, 2026.

The comparison of dividend payments during the past 3 years is detailed as follows:

Description	2025 (proposed year)	2024	2023
Dividend Payment (Million Baht)	44.19	-	129.376
● Dividend for year (Baht : share)	0.073	-	0.3473
○ Stock Dividend Payout Ratio (Existing Share : Stock Dividend)	-	-	8 : 5
○ Stock Dividend Payout Ratio (Baht : Share)	-	-	0.3125
○ Cash Dividend Payout Ratio (Baht : Share)	-	-	0.0348
Dividend Payment to Net Profit Ratio (%)	60.00	-	62.12

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 5 To consider and approve the directors' remuneration for the year 2026

Objective and Rationale: According to Section 90 of the Public Company Limited Act B.E. 2535 (1992) (as amended) and Article 26 of the Company's Articles of Association, Directors are eligible for remuneration in forms of rewards, meeting allowance, gratuity, bonus or other benefit according to the resolution of the Shareholders' Meeting by not less than two-thirds (2/3) of the total number of votes of the shareholders attending the meeting and having the right to vote.

Opinion of the Nomination and Remuneration Committee: The Nomination and Remuneration Committee conducted a survey on remuneration for the Board of Directors and sub-committees for the year 2026, considering the suitability from the scope of duties and responsibilities, the responsibilities and performance of the Board of Directors and each sub-committee, business expansion, the Company's performance and comparative information with other companies in the same industry with similar size and nature of the business and considered appropriate to maintain the remuneration of the Board of Directors and sub-committees, including monthly remuneration and meeting allowance at the same rate as year 2025.

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the remuneration of the Board of Directors and sub-committees for the year 2026 (proposed year) at the same rate as year 2025 as proposed by the Nomination and Remuneration Committee who had taken into consideration various factors and criteria as follows:

Position	2026 (proposed year)	2025
Monthly remuneration (person : month) For non-executive directors <ul style="list-style-type: none"> ● Chairman ● Director 	30,000 Baht 20,000 Baht	30,000 Baht 20,000 Baht
Meeting Allowance For non-executive director (Baht : time) (pay only to meeting attendee) <u>Board of Directors</u> <ul style="list-style-type: none"> ● Chairman ● Director 	20,000 Baht 15,000 Baht	20,000 Baht 15,000 Baht
<u>Audit Committee</u> <ul style="list-style-type: none"> ● Chairman ● Director 	22,500 Baht 15,000 Baht	22,500 Baht 15,000 Baht

Position	2026 (proposed year)	2025
<u>Nomination and Remuneration Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht
<u>Corporate Governance and Sustainable Development Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht
<u>Risk Management Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht
Other Benefits	None	None

The Company has a policy to pay bonuses to independent directors and non-executive directors (as a whole) of not more than 0.5% of the total dividend declared for payment. By assigning the Board of Directors and/or any person(s) authorized by the Board of Directors to further consider and allocate the bonus to the independent directors and non-executive directors.

In this regard, the total monthly remuneration, meeting allowances, and other benefits combined shall not exceed Baht 4 million per year.

Details of the Board of Directors' remuneration for 2025 are disclosed in the Annual Registration Statement/Annual Report 2025 (Form 56-1 One Report 2025) under Section 8: Key Corporate Governance Performance Report, Subsection 8.1.2 Directors' Remuneration.

Voting: This agenda must be approved by a vote of not less than two-thirds of the total number of votes of the shareholders who attend the meeting and have the right to vote.

Agenda 6 To consider and approve the appointment of directors in replacement of those who must retire by rotation

Objective and Rationale: According to Section 71 of the Public Limited Company Act B.E. 2535 (1992) (including any amendment thereto) and Article 21 of the Company's Articles of Association, at every Annual General Meeting of Shareholders, one-third of the directors shall retire from office. If the number of directors cannot be divided exactly into three parts, the number closest to one-third shall retire. Directors retiring by rotation are eligible for re-election.

The 2026 Annual General Meeting of Shareholders, there are 3 directors who have completed their term of office as follows:

1. Clinical Professor Emeritus Udom Kachintorn, MD. Independent Director, Chairman and Chairman of the Corporate Governance and Sustainable Development Committee
2. Dr. Trinnawat Thanitnithiphan Director, Nomination and Remuneration Committee, Risk Management Committee and Chairman of Executive Committee
3. Ms. Napaporn Dechakarat Director, Risk Management Committee and Executive Committee

The Company provides an opportunity for shareholders to propose agendas and nominate candidates to be elected as directors during October 1, 2025 – December 31, 2025, in which there were no shareholders proposing agendas and names of persons to be considered for election as a director.

Opinion of the Nomination and Remuneration Committee: The Nomination and Remuneration Committee (excluding the stakeholders) has carefully reviewed before presenting to the Board of Directors and to propose to the Annual General Meeting of Shareholders for election directors, considering the qualifications of directors as specified in the relevant laws, the Company's regulations, proportion and qualification of Independent Directors according to the definition of Independent Director of the Company, as well as knowledge, capabilities and experience that are useful to the Company's business. The Nomination and Remuneration Committee deemed it appropriate to propose the appointment of Clinical Professor Emeritus Udom Kachintorn, MD., Dr. Trinnawat Thanitnithiphan and Ms. Napaporn Dechakarat to return to serve as Directors for another term. The Nomination and Remuneration Committee considered that all candidates nominated have all qualifications as specified by relevant regulations and suitable for the business, and the candidates nominated as independent directors are fully qualified in accordance with the law and regulations relating to independent directors and are able to provide opinions independently. Profiles and working experiences of the candidates nominated for election as the directors in place of those who retire by rotation in **Attachment No. 3**.

Opinion of the Board of Directors: The Board of Directors (excluding stakeholders) considered the list of nominated persons, which has been carefully screened and considered by the Nomination and Remuneration Committee, and deemed it appropriate to propose to the Annual General Meeting of Shareholders to appoint 3 directors, namely Clinical Professor Emeritus Udom Kachintorn, MD., Dr. Trinnawat Thanitnithiphan, and Ms. Napaporn Dechakarat to return to serve as Directors for another term. The Board of Directors considered that the candidates nominated as an Independent Directors have all qualifications as specified by relevant regulations and can provide independent opinions.

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 7: To consider and approve the appointment of auditor and fix his/her remuneration for the year 2026

Objective and Rationale: According to Section 120 of the Public Company Limited Act B.E. 2535 (1992) (as amended), which stipulates that the Annual General Meeting of Shareholders shall appoint auditors and determine audit fees every year. In appointing the auditor, the same auditor may be reappointed.

Opinion of the Audit Committee: The Audit Committee has considered and approved the selection of auditors from EY Office Limited to be the auditors of the Company and its subsidiaries for the year 2026, which has been the same auditor for the sixth consecutive year. EY Office Limited has satisfactorily performed its duties to the Company in accordance with the auditing standards and provided useful opinions to the Company and independent and agreed that the audit fee proposed by EY Office Limited was appropriate, when compared to the scope of service and workload.

Opinion of the Board of Directors: With careful consideration Audit Committee, The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to appoint auditors from EY Office Limited, which is the same auditor as the Company's subsidiaries, whereby one of the following auditors will be appointed as the auditor of the Company for the year 2026.

1. Ms. Siriwan Nitdamrong Certified Public Accountant No. 5906 and / or
2. Ms. Kamontip Lertwitworathep Certified Public Accountant No. 4377 and / or
3. Mrs. Sarinda Hirunprasurtwutti Certified Public Accountant No. 4799 and / or
4. Mr. Somsak Chiratdhitiampiyong Certified Public Accountant No. 8874

All above four auditors are qualified and has no relationship or any conflict of interest with the Company, its subsidiaries and associates, management, major shareholders or any person related to such person. Therefore, there is independence in auditing and express an opinion on the Company's financial statements, its subsidiaries and associates including the certified auditors as above, no auditors have performed the audit duties of the Company for more than the period specified in the relevant announcement. (Profiles of the Auditors proposed for the year 2026, Attachment No. 4).

The Board of Directors also deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the audit fees of the Company for the year 2026 as follows:

(Unit : Baht)

List of services	2026 (proposed year)	2025	Increase/(Decrease)
Audit fee of the Company	2,380,000	2,180,000	200,000
Other service*	None	450,000	-

Remark: *Other service fees shall be charged based on actual expenses incurred.

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 8 To consider and approve the issuance and offering of warrants to purchase of newly issued ordinary shares for allocation to Executive and/or Employees of the Company of Its Subsidiaries (IP ESOP-W1)

Objective and Rationale: To incentivize executives and employees who demonstrate strong performance and dedication in carrying out their duties to continue working with the Company in order to achieve its long-term business objectives, and to retain knowledgeable and capable personnel with key skills critical to the Company's core business for long-term employment, as well as to raise working capital in the event of the exercise of the warrants.

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders for consideration the issuance of warrants to purchase newly issued ordinary shares of the Company to be allocated to executives and/or employees of the Company or its subsidiaries (IP ESOP-W1) in a total amount of not exceeding 4,500,000 units, representing 0.74% of the total issued and paid-up shares of the Company. The warrants shall be allocated free of charge, with an exercise ratio of 1 warrant unit to 1 newly issued ordinary share. The term of IP ESOP-W1 shall not exceed three (3) years from the issuance date, as detailed in **Attachment No. 5**.

In this regard, the Board of Directors and/or the Company's authorized directors and/or any person(s) authorized by the Board of Directors or the Company's authorized directors shall be authorized to consider and determine any other necessary details in connection with the issuance and allocation of IP ESOP-W1, including but not limited to:

(1) determining the list of executives and/or employees of the Company or its subsidiaries who are entitled to receive the allocation of warrants and the number of warrants to be allocated to each individual;

(2) determining, amending, or adding any details and conditions necessary and related to the issuance of IP ESOP-W1 to the extent permitted by law or in non-material matters, such as the date, time, and method of issuance and allocation of IP ESOP-W1, and the method of exercise of the warrants;

(3) negotiating, entering into agreements, and executing relevant documents and contracts, and undertaking any actions in connection with the allocation of IP ESOP-W1; and

(4) signing applications for approval, and submitting relevant documents and evidence in connection with the allocation of IP ESOP-W1, including contacting and submitting applications and required documents to relevant government authorities, listing the newly issued ordinary shares on the Stock Exchange of Thailand, and taking any other necessary actions in relation to the allocation of IP ESOP-W1.

In addition, no executive or employee shall be allocated warrants in excess of 5% of the total number of warrants to be issued. The Company shall complete the allocation of the warrants within one (1) year from the date of approval by the shareholders' meeting.

Voting: This agenda must be approved by a vote of not less than three-fourths (3/4) of the total voting rights of shareholders present at the meeting and entitled to vote, with no shareholders holding in aggregate more than ten percent (10) of the total voting rights of shareholders present and voting opposing the issuance and offering of the warrants (IP ESOP-W1), in accordance with the Notification of the Capital Market Supervisory Board No. TorJor. 32/2008 Re: Offering of Newly Issued Securities to Directors or Employees.

Agenda 9: To consider and approve the reduction of registered capital and the amendment to the Company's Memorandum of Association to reflect the capital reduction

Objective and Rationale: According to Section 136 of the Public Limited Companies Act B.E. 2535 (1992), as amended, a company may increase its capital only after all shares have been issued and fully paid, except for shares reserved for the exercise of warrants to purchase shares. The Company intends to reduce its registered capital by cancelling 151,430,255 unissued shares. Currently, the Company has a registered capital of Baht 378,387,365, divided into 756,774,730 ordinary shares with a par value of Baht 0.50 per share, and a paid-up capital of Baht 302,672,237.50, divided into 605,344,475 ordinary shares with a par value of Baht 0.50 per share. At present, the Company has 151,430,255 unissued ordinary shares, comprising:

1. Reserve for exercise the rights of the warrants to purchase ordinary shares of the Company No. 2 (IP-W2) of 93,129,515 shares;
2. Additionally, reserved for the adjustment of the rights of the warrants to purchase ordinary shares of the Company No. 2 (IP-W2) of 58,299,187 shares; and
3. Remaining from the reservation for stock dividend payment 1,553 shares

Accordingly, it is deemed appropriate to reduce the Company's registered capital by cancelling 151,430,255 unissued ordinary shares and to amend Clause 4 of the Company's Memorandum of Association to reflect such reduction of registered capital.

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the capital decrease of Baht 75,715,127.50 from the registered capital of Baht 378,387,365 to Baht 302,672,237.50 by canceling 151,430,255 shares unpaid-up ordinary shares with a par value of Baht 0.50 per share, and approve the amendment of Article 4 of the Company's Memorandum of Association to comply with the decrease of the Company's registered capital as follows;

"Article 4. Registered capital	302,672,237.50	Baht	(Three hundred two million six hundred seventy-two thousand two hundred thirty-seven Baht and fifty Satang)
Divided into	605,344,475	shares	(Six hundred five million three hundred forty-four thousand four hundred seventy-five shares)
Par value	0.50	Baht	(Fifty Satang)
Divided into			

Ordinary shares	605,344,475	shares	(Six hundred five million three hundred forty-four thousand four hundred seventy-five shares)
Preferred shares	- None –	-”	

In addition, the Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders the authorization to the authorized directors of the Company in accordance with the Company’s affidavit or any person authorized by such authorized directors to have the authority to undertake any necessary actions for the registration of the amendment of the Memorandum of Association as approved until completion.

Voting: This agenda must be approved by a vote of not less than three-fourths of the total number of votes of shareholders attending the meeting who are entitled to vote.

Agenda 10: To consider and approve the increase of registered capital and the amendment to the Company’s Memorandum of Association to reflect the capital increase

Objective and Rationale: As the Company intends to increase its registered capital by Baht 2,250,000, from the existing registered capital of Baht 302,672,237.50 to Baht 304,922,237.50, by issuing 4,500,000 newly issued ordinary shares with a par value of Baht 0.50 per share, to accommodate the exercise of warrants to purchase newly issued ordinary shares of the Company to be allocated to executives and/or employees of the Company or its subsidiaries (IP ESOP-W1), and to amend Clause 4 of the Company’s Memorandum of Association to reflect such increase in registered capital.

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders for approval the increase of the Company’s registered capital by Baht 2,250,000, from the existing registered capital of Baht 302,672,237.50 to Baht 304,922,237.50, by issuing 4,500,000 newly issued ordinary shares with a par value of Baht 0.50 per share, to accommodate the exercise of warrants to purchase newly issued ordinary shares of the Company (IP ESOP-W1), and to amend Clause 4 of the Company’s Memorandum of Association to reflect the increase in the Company’s registered capital as follows:

“Article 4. Registered capital	304,922,237.50	Baht	(Three hundred four million nine hundred twenty-two thousand two hundred thirty-seven Baht and fifty Satang)
Divided into	609,844,475	shares	(Six hundred nine million eight hundred forty-four thousand four hundred seventy-five shares)
Par value	0.50	Baht	(Fifty Satang)
Divided into			
Ordinary shares	609,844,475	shares	(Six hundred nine million eight hundred forty-four thousand four hundred seventy-five shares)

Preferred shares - None – -”

In addition, the Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders the authorization to the authorized directors of the Company in accordance with the Company's affidavit or any person authorized by such authorized directors to have the authority to undertake any necessary actions for the registration of the amendment of the Memorandum of Association as approved until completion.

Voting: This agenda must be approved by a vote of not less than three-fourths of the total number of votes of shareholders attending the meeting who are entitled to vote.

Agenda 11: To consider and approve the allocation of newly issued ordinary shares to accommodate the exercise of the IP ESOP-W1

Objective and Rationale: Further to the registered capital increase plan under Agenda Item 10 above, the Company will allocate up to 4,500,000 newly issued ordinary shares with a par value of Baht 0.50 per share to accommodate the exercise of the IP ESOP-W1.

Opinion of the Board of Directors: The Board of Directors has considered and deems it appropriate to propose to the Annual General Meeting of Shareholders for approval the allocation of up to 4,500,000 newly issued ordinary shares to accommodate the exercise of rights under the IP ESOP-W1 warrants, to be allocated to the Company's executives and/or employees of the Company or its subsidiaries.

In this regard, the Board of Directors and/or the Chief Executive Officer and/or any person designated by the Board of Directors and/or the Chief Executive Officer shall be authorized to determine, amend, and change any terms and conditions and other details relating to the issuance and allocation of such newly issued ordinary shares, including but not limited to:

- (1) Changes to the conditions and other details related to the adjustment or change of the exercise ratio and exercise price, in accordance with the terms and conditions.
- (2) Entering into negotiations, make agreements, and sign relevant documents and contracts, as well as take any necessary and appropriate actions related to the allocation of the newly issued ordinary shares.
- (3) Sign the application for permission, waiver, and evidence necessary and related to the issuance and offering of such newly issued ordinary shares, including but not limited to providing information and submitting documents and evidence to the Securities and Exchange Commission, the Stock Exchange of Thailand, Thailand Securities Depository Co., Ltd., Ministry of Commerce, or other related agencies. They are also authorized to take any other actions necessary and relevant to the issuance and offering of such newly issued ordinary shares, including listing them as securities on the Stock Exchange of Thailand.
- (4) Take necessary action to reassemble and distribute the newly issued ordinary shares.

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 12 To consider any other matters (if any)

In convening the 2026 Annual General Meeting of Shareholders, the Company has complied with the principles of good corporate governance. During the period from 1 October 2025 to 31 December 2025, the Company provided shareholders with the opportunity to propose qualified candidates for consideration as directors and to propose meeting agenda items in advance of the Annual General Meeting. Upon the expiration of such period, it appeared that no shareholders proposed any candidates for consideration as directors, and no agenda items were proposed.

Therefore, we would like to invite the shareholders to attend the 2026 Annual General Meeting of Shareholders on **Monday, April 27, 2026 at 14.00 hrs. via Electronic means (E-Meeting) only**. Shareholders can submit a registration form for a meeting via E-Meeting as per **Attachment No. 10** and identity verification documents to the Company by **April 22, 2026**. The company will open registration to attend the meeting via electronic media on **Monday, April 27, 2026 at 12.00 hrs.** until the meeting is adjourned.

The Company has published this invitation letter for the 2026 Annual General Meeting of Shareholders together with supporting documents and Proxy form; Form A, Form B and Form C which are available on the Company website at www.interpharma.co.th, section Investor Relation or can request a hard copy of the proxy form via email at comsec@interpharma.co.th 14 days prior to the meeting.

For shareholders who wish to appoint a proxy to attend and vote on their behalf in the meeting, please kindly complete and duly sign either Proxy Form A or Form B provided herewith as per **Attachment No. 8** or download them at www.interpharma.co.th and execute only one of the aforementioned forms. A shareholder who wishes to appoint an independent director of the Company to be a Proxy to attend and vote on behalf of shareholders whom of which is Mr. Kamtorn Sila-On and/or Dr. Pao Sriprasertsuk information of the independent directors proposed by the Company to be the Shareholders' Proxies as per **Attachment No. 7** and submit the completed Proxy Form with the required documents to the Company in advance so that the Company receives them by **Wednesday, April 22, 2026**.

In addition, the shareholders can send questions related to the agenda of the 2026 Annual General Meeting of Shareholders or other important information prior to the meeting date via e-mail: comsec@interpharma.co.th or by post to the Company Secretary, Inter Pharma Public Company Limited at No. 140/9 ITF Tower 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500.

-Signature-

(Dr. Trinnawat Thanitnithiphan)

Chief of Executive Officer

For more information, please contact:

Office of Company Secretary:

Tel. 02-634-0225 ext. 18